United Kingdom-based ViiV Healthcare has reported that two phase three trials assessing the two-drug regimen (2DR) of dolutegravir (Tivicay) and lamivudine (Epivir) in treatment naive HIV-1 infected adults demonstrated the ability to control HIV.

It was reported on Friday that the trials, named GEMINI-1 and GEMINI-2, evaluated the 2DR against a three-drug regimen of dolutegravir and two nucleoside reverse transcriptase inhibitors in HIV-1 patients with baseline viral loads under 500,000 copies per ml. The nucleoside reverse transcriptase inhibitors used in the trials were tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC). Non-inferiority based on plasma HIV-1 RNA